Table 2 Clinical and therapeutic data of the study ARD patients according to their decision to receive a booster dose of COVID-19 vaccine (n = 248)
Variables Median (min–max) or n (%) | Total (n = 248) | Booster dose acceptant group (n = 79) | Booster dose hesitant group (n = 36) | Booster dose resistant group (n = 133) | P |
|---|---|---|---|---|---|
The rheumatic/autoimmune disease | |||||
Systemic lupus erythematosus Rheumatoid arthritis Juvenile idiopathic arthritis Systemic sclerosis Myositis Vasculitis Sjögren's syndrome Mixed connective tissue disease Ankylosing spondylitis Psoriatic arthritis Gout Osteoarthritis Osteoporosis Fibromyalgia Behcet's disease Familial Mediterranean fever Others | 90 (36.3) 67 (27.0) 1 (.4) 5 (2.0) 1 (.4) 4 (1.6) 4 (1.6) 3 (1.2) 4 (1.6) 7 (2.8) 3 (1.2) 36 (14.5) 6 (2.4) 5 (2.0) 3 (1.2) 2 (.8) 7 (2.8) | 21 (26.6) 18 (22.8) 0 1 (1.3) 1 (1.3) 1 (1.3) 1 (1.3) 1 (1.3) 2 (2.5) 2 (2.5) 0 3 (3.8) 19 (24.1) 2 (2.5) 1 (1.3) 2 (2.5) 2 (2.5) | 20 (55.6) 6 (16.7) 0 2 (5.6) 0 0 1 (2.8) 1 (2.8) 0 0 0 3 (8.3) 1 (2.8) 0 0 0 1 (2.8) | 49 (36.8) 43 (32.3) 1 (.8) 2 (1.5) 0 3 (2.3) 2 (1.5) 1 (.8) 2 (1.5) 5 (3.8) 0 14 (10.5) 2 (1.5) 3 (2.3) 2 (1.5) 0 4 (3.0) | 0.164 |
Disease duration (years) | 5 (0.1–35) | 5.5 (.10–32) | 4 (.25–20) | 5 (.10–35) | 0.066 |
Self-reported health status | |||||
Poor Fair Good | 41 (16.5) 147 (59.3) 60 (24.2) | 12 (15.2) 42 (53.2) 12 (15.2) | 3 (8.3) 23 (63.9) 10 (27.8) | 26 (19.5) 82 (61.7) 25 (18.8) | 0.156 |
Associated comorbidities | |||||
Hypertension Diabetes mellitus Chronic kidney disease Heart disease Lung disease | 71 (28.6) 25 (10.1) 28 (11.3) 11 (4.4) 21 (8.5) | 27 (34.2) 8 (10.1) 4 (5.1) 5 (6.3) 4 (5.1) | 11 (30.6) 3 (8.3) 7 (19.4) 2 (5.6) 4 (11.1) | 33 (24.8) 14 (10.5) 17 (12.8) 4 (3.0) 13 (9.8) | 0.332 0.927 0.057 0.493 0.776 |
Therapeutic data | |||||
Corticosteroids | 141 (56.9) | 34 (43.0) | 24 (66.7) | 83 (62.4) | 0.010* |
cDMARDs | |||||
Methotrexate Hydroxychloroquine Mycophenolate mofetil Leflunomide | 57 (23.0) 128 (51.6) 34 (13.7) 45 (18.1) | 11 (13.9) 29 (36.7) 9 (11.4) 14 (17.7) | 10 (27.8) 23 (63.9) 8 (22.2) 4 (11.1) | 36 (27.1) 76 (57.1) 17 (12.8) 27 (20.3) | 0.068 0.004* 0.264 0.444 |
Biologics | |||||
TNF-alpha inhibitors Interleukin-6 inhibitors Interleukin-17 inhibitors JAK-inhibitors Rituximab | 9 (3.6) 3 (1.2) 4 (1.6) 2 (.8) 7 (2.8) | 0 1 (1.3) 1 (1.3) 1 (1.3) 2 (2.5) | 1 (2.8) 0 0 0 1 (2.8) | 8 (6.0) 2 (1.5) 3 (2.3) 1 (.8) 4 (3.0) | 0.074 0.764 0.608 0.776 0.980 |
Prior COVID-19 infection | 110 (44.4) | 30 (38.0) | 18 (50.0) | 62 (46.6) | 0.360 |
COVID-19 among relatives or friends | 162 (65.3) | 44 (55.7) | 27 (75.0) | 91 (68.4) | 0.071 |
COVID-19 vaccination | 179 (72.2) | 78 (98.7) | 25 (69.4) | 76 (57.1) | < 0.001* |